JavaScript is disabled in your web browser or browser is too old to support JavaScript. Today almost all web pages contain JavaScript, a scripting programming language that runs on visitor's web ...
JavaScript is disabled in your web browser or browser is too old to support JavaScript. Today almost all web pages contain JavaScript, a scripting programming language that runs on visitor's web ...
Ocular Therapeutix Inc. (NASDAQ: OCUL) shares are down during Tuesday's premarket session following a significant announcement regarding their Axpaxli treatment for wet age-related macular ...
BEDFORD, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today ...
Ocular to host webcast scheduled for Tuesday, February 17, 2026, at 8:00 AM ET Detailed SOL-1 data to be presented at the 49 th Macula Society Annual Meeting BEDFORD, Mass., Feb. 13, 2026 (GLOBE ...
Ocular Therapeutix (OCUL) is a Strong Buy, driven by the pivotal SOL-1 Phase 3 trial for AXPAXLI™ in wet AMD, with topline results expected Q1 2026. AXPAXLI™ leverages proven science and a de-risked ...
Monday - Friday, 08:00 - 11:00 CET | 14:00 - 17:00 HK/SG ING CFO, Tanate Phutrakul, discusses 2025 earnings, growth in Europe and the impact AI is having on jobs within the bank. Got a confidential ...
(RTTNews) - Shares of Ocular Therapeutics, Inc. (OCUL), are up 23% in pre-market trading today, reflecting investor enthusiasm around the company's late-stage pipeline in retinal and glaucoma programs ...
PARIS/MADRID, Dec 2 (Reuters) - A group of 10 European banks, including ING (INGA.AS), opens new tab, UniCredit (CRDI.MI), opens new tab and BNP Paribas (BNPP.PA), opens new tab, have formed a company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results